Cyclophosphamide with granulocyte colony stimulating factor (G-CSF) is commonly used to mobilize stem cells in multiple myeloma. Timing of collection is variable and incidence and severity of side effects is substantial. To optimize timing of collection, to reduce side effects and to limit costs of the procedure, we evaluated vinorelbine, a drug shown to have activity in multiple myeloma, in combination with G-CSF as mobilizing regimen. A total of 19 consecutive patients with advanced stage multiple myeloma received one dose of vinorelbine 35 mg/m 2 intravenously on day 1 in an outpatient setting and G-CSF 10 lg/kg/day from day 4 divided in two daily doses. Median CD34+ cell blood counts measured on day 8 of mobilization were 142 Â 10 6 /l (range 57-467). One 15-l apheresis on day 8 resulted in sufficient stem cells (median 11.1 Â 10 6 CD34+ cells/kg, range 6.2-36.0 prior and median 7.5 Â 10 6 CD34+ cells/kg, range 4.0-20.2 postpositive CD34+ cell selection) for transplantation. Hematopoietic recovery was swift with ANC 40.5 Â 10 9 /l on day 11 median (range 10-15) and platelets 420 Â 10 9 /l on day 12 median (range 10-15) after reinfusion of the stem cells on day 0. No episodes of febrile neutropenia were observed during mobilization. In our institutions cost reduction for the procedure was about 1700 euros compared to the mobilization with cyclophosphamide and G-CSF. Vinorelbine and G-CSF allow precise timing and harvesting of sufficient stem cells, and might be an alternative to cyclophosphamide in the mobilization of stem cells for autologous transplantation in multiple myeloma.
Summary:
Cyclophosphamide with granulocyte colony stimulating factor (G-CSF) is commonly used to mobilize stem cells in multiple myeloma. Timing of collection is variable and incidence and severity of side effects is substantial. To optimize timing of collection, to reduce side effects and to limit costs of the procedure, we evaluated vinorelbine, a drug shown to have activity in multiple myeloma, in combination with G-CSF as mobilizing regimen. A total of 19 consecutive patients with advanced stage multiple myeloma received one dose of vinorelbine 35 mg/m 2 intravenously on day 1 in an outpatient setting and G-CSF 10 lg/kg/day from day 4 divided in two daily doses. Median CD34+ cell blood counts measured on day 8 of mobilization were 142 Â 10 6 /l (range 57-467). One 15-l apheresis on day 8 resulted in sufficient stem cells (median 11.1 Â 10 6 CD34+ cells/kg, range 6.2-36.0 prior and median 7.5 Â 10 6 CD34+ cells/kg, range 4.0-20.2 postpositive CD34+ cell selection) for transplantation. Hematopoietic recovery was swift with ANC 40.5 Â 10 9 /l on day 11 median (range 10-15) and platelets 420 Â 10 9 /l on day 12 median (range 10-15) after reinfusion of the stem cells on day 0. No episodes of febrile neutropenia were observed during mobilization. In our institutions cost reduction for the procedure was about 1700 euros compared to the mobilization with cyclophosphamide and G-CSF. Vinorelbine and G-CSF allow precise timing and harvesting of sufficient stem cells, and might be an alternative to cyclophosphamide in the mobilization of stem cells for autologous transplantation in multiple myeloma. Bone Marrow Transplantation (2003) 31, 99-103. doi:10.1038/sj.bmt.1703787 Keywords: PBSC mobilization; multiple myeloma; vinorelbine; G-CSF Intensive chemotherapy with autologous stem cell transplantation is an accepted treatment modality in patients with multiple myeloma [1] [2] [3] [4] [5] . In most cases, cyclophosphamide at doses of 4-7 g/m 2 and granulocyte colonystimulating factor (G-CSF) are used to mobilize stem cells into the peripheral blood. [6] [7] [8] [9] [10] Cyclophosphamide given over 2 days in two divided doses, hyperhydration and the uroprotectant mesna led to a decrease in nonhematological toxicity, but may require hospitalization for safe administration. Several days of administration of G-CSF lead to CD34+ cell peak values at a median of 2-3 weeks after cyclophosphamide. 9, 10 The day of CD34+ cell peak value varies considerably and is unpredictable for an individual patient, thus requiring monitoring of WBC and/or CD34+ cell blood counts for several days. Although a sufficient number of peripheral blood progenitor cells (PBPC) can be collected with cyclophosphamide and G-CSF, in some instances febrile neutropenia has been encountered, requiring hospitalization and intravenous antibiotics. 9, 10 Vinorelbine, a new semisynthetic vinca alkaloid, has successfully been used with low toxicity in the treatment of solid tumors. In phase II studies vinorelbine has shown activity in multiple myeloma. 11, 12 Its main side effect is neutropenia. These two features have prompted us to study vinorelbine as a mobilizing agent for PBPC collection in multiple myeloma. Ifosfamide/vinorelbinebased chemo-therapy with G-CSF has been shown to mobilize successfully stem cells in patients with malignant lymphoma. 13 As vinorelbine can be administered in an outpatient setting, we also analyzed the cost in comparison to the mobilization with cyclophosphamide.
Patients and methods

Patients
In all, 19 consecutive patients were enrolled into this prospective two center phase I/II study to receive vinorelbine followed by G-CSF. Inclusion criteria were high-risk multiple myeloma defined as stage III (n ¼ 15), stage II (n ¼ 1) at diagnosis according to the Durie-Salmon classification 14 or light chain disease (n ¼ 3), age o65 years and chemosensitivity to conventional cytotoxic chemotherapy with vincristine, adriamycin, and dexamethasone (VAD). The main characteristics of patients are presented in Table 1 . Prior chemotherapy consisted of three cycles of VAD in 17 patients, two cycles in one patient, and two series of three cycles in one patient. Patients were not exposed to alkylating agents. In addition, four patients pretreated with melphalan and steroids were also mobilized according to the study protocol (Table 2) , after three cycles of VAD.
The study protocol was approved by the local ethical committee. Written informed consent was obtained from all patients. 
PBPC mobilization
Vinorelbine was administered at a dose of 35 mg/m 2 intravenously over 5-10 min in an outpatient setting on day 1. Hydration or antiemetic drugs were not used. G-CSF 10 mg/kg/day subcutaneously divided into a morning and an evening dose was started on day 4 and was continued daily until apheresis.
Collection protocol
As there is a good correlation between circulating CD34+ cells and progenitor cell yield in the apheresis products, WBC and circulating CD34+ cells in peripheral blood were monitored to determine the timing of PBPC harvest. 15, 16 Apheresis was performed when the peripheral CD34+ cell count was 420 Â 10 6 /l, using a Cobe Spectra or Amicus cell separator processing 15 liters of blood by continuous flow. Set as target by our protocol, no additional apheresis was planned if the number of CD34+ cells in the collected apheresis product exceeded 44 Â 10 6 /kg body weight of the patient.
Flow cytometry and colony assays
Cells of blood samples and cells of the PBPC collection expressing the surface membrane antigen CD34 were identified and quantified using a FACScan flow cytometer (Becton Dickinson) according to a published guideline. 17 The proliferation capacity of the CD34+ enriched product was assessed using a semisolid clonogenic assay.
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CD34+ enrichment of the transplant CD34+ positive selection was performed using Baxter Isolex 300 according to the instructions of the manufacturer. The enriched product was frozen in a controlled rate freezer with dimethylsulfoxide (DMSO) at a concentration of 10% as a cryoprotectant and stored in vapor-phase nitrogen until transplantation.
Pre-transplantation conditioning regimen
All patients were treated with high-dose melphalan 200 mg/ m 2 with support of autologous peripheral stem cells on day 0.
Control patients
A historical control group, treated with the standard protocol, as used prior to this experimental protocol, of 12 consecutive patients, pretreated with an average of three cycles of VAD and mobilized with high-dose cyclophosphamide (4 g/m 2
) and G-CSF 10 mg/kg/day subcutaneously divided in a morning and evening dose started on day 7 and continued daily until apheresis, was used to compare stem cell number in the blood and in the collected transplant product, and day of apheresis of the two procedures (Table 3 ). In addition, a group of allogeneic stem cell donors mobilized by G-CSF alone (10 mg/kg/day subcutaneously) for 5 days was analyzed to compare WBC and CD34+ stem cell blood count.
Cost analysis
Costs for mobilization with vinorelbine and G-CSF were compared to historical controls (n ¼ 12) mobilized with high-dose cyclophosphamide (4 g/m 2 ) and G-CSF. Taken into account were costs of hospitalization for the application of cyclophosphamide, chemotherapy, mesna, antiemetics, G-CSF, and of WBC and CD34 measurements before collection. All other procedures did not differ between the two mobilizing regimens; therefore, they do not have an impact on the comparison of costs.
Statistical analysis
The Mann-Whitney U-test was used to compare WBC, CD34+ cells in percent, CD34+ cells per ml in the blood prior to stem cell collection, and CD34+ cells in the collected products of the study group and the historical controls.
Results
A total of 19 consecutive patients pretreated with VAD were mobilized with vinorelbine and G-CSF. The characteristics of the patients are shown in Table 1 In the four patients with prior exposure to melphalan, stem cell collection was performed on median day 8.5 (range 8-9) after vinorelbine administration with a median WBC of 8.8 Â /l (range 50-528), respectively ( Table 3) . The numbers of CD34+ cells in the transplant were median 20.5 Â 10 6 /kg body weight (range 3.1-39.3, n ¼ 11) before manipulation of the graft. Three of these 12 patients were hospitalized following the administration of cyclophosphamide with febrile neutropenia and received intravenous antibiotics.
The group of 20 allogeneic stem cell donors showed a median WBC after 5 days of G-CSF of 48.1 Â 10 9 /l (range 29.6-72.6), a median of 0.18% CD34+ cells (range 0.03-0.56), and a median of 86 Â 10 6 /l CD34+ cells (range 13-213) in the blood.
Compared to stimulation with G-CSF alone, mobilization with vinorelbine and cyclophosphamide resulted in statistically significant higher CD34+ cells per liter (po0.01) and CD34+ cells in percent (po0.01) in the blood prior to collection, but there was no statistical difference in these parameters between vinorelbine and cyclophosphamide mobilization (p40.4). There were no significant differences in CD34+ content either before or after manipulation among patients mobilized with vinorelbine and G-CSF or cyclophosphamide and G-CSF (p40.4).
Drug costs of both mobilization schemes used in our institutions were analyzed for a standardized patient with 1.7 m 2 body surface. Cyclophosphamide 4 g/m 2 and 60% mesna equal the cost of vinorelbine 35 mg/m 2 . Antiemetics (Ondansetron 8 mg orally) were only used for cyclophosphamide accounting for 16 euros. The major differences in costs were in the number of days of G-CSF application, where for cyclophosphamide a median of two additional days was necessary to mobilize stem cells, accounting for an additional 600 euros. Two days of hospitalization for the application of cyclophosphamide and mesna make a difference of 1100 euros. In total, mobilization with vinorelbine reduces costs by about 1700 euros. We are aware that other regimens of application of cyclophosphamide may lead to other cost calculations and that these regimens should be compared accordingly. If the patient suffers from febrile neutropenia, as it occurred in three out of the 12 patients mobilized with cyclophosphamide, the costs increase substantially with hospitalization and administration of antibiotics.
Discussion
Patients mobilized with an easy-to-administer outpatient regimen of vinorelbine and G-CSF show a consistent high yield of stem cells at a reliable interval of 8 days after the start of the treatment. A single apheresis allows the collection of sufficient stem cells to perform a safe transplantation with rapid engraftment after infusion of the stem cells indicating that the mobilizing procedure with vinorelbine and G-CSF does not decrease the in vivo proliferation capacity of the harvested stem cells. This regimen with a well-defined time point of collection also allows an easier scheduling and better resource utilization of the different teams involved in CD34+ cell measurement, stem cell apheresis, and graft manipulation.
The comparison with a historical group of patients mobilized with cyclophosphamide and G-CSF shows a yield of harvested stem cells of the same magnitude between the two mobilizing procedures. In contrast, the time point of collection for patients mobilized with cyclophosphamide and G-CSF varied considerably and two additional days of G-CSF administration were necessary. Although the time point of stem cell harvesting was not part of a study protocol in the historical group mobilized with cyclophosphamide, the variation of the day of apheresis indicates that prediction of the corresponding day will be difficult. Three out of 12 patients mobilized with cyclophosphamide and G-CSF had to be hospitalized due to febrile neutropenia and intravenous antibiotics had to be administered, whereas none of the vinorelbine and G-CSF mobilized patients showed an infection. In fact, no patient in our study showed any signs of toxicity.
The higher percentage of mobilized CD34+ stem cells with vinorelbine and G-CSF of median 0.79% (range 0.29-2.86%) compared to a control group of allogeneic stem cell donors with median 0.18% (range 0.03-0.56%) indicates that G-CSF alone cannot be responsible for the yield of mobilized stem cells encountered with the combination with vinorelbine. In addition, vinorelbine is said to have antimyeloma activity, although the value of such an effect in the setting of mobilizing stem cells has been debated even with the administration of cyclophosphamide. 10 As the time frame after stem cell mobilization and start of the conditioning regimen was very short, we did not evaluate the anti-myeloma effect in this study. Although we included only four patients that were pretreated with melphalan and steroids, the results obtained after mobilization with vinorelbine and G-CSF allow the conclusion that this regimen is also feasible in pretreated patients.
The easier scheduling of harvesting after outpatient administration of the regimen with better resource utilization, shorter administration of G-CSF, and lower risk of hospitalization because of febrile neutropenia leads to a more effective cost control of the procedure.
Our study makes this mobilization regimen with vinorelbine and G-CSF an interesting alternative to the mobilization with cyclophosphamide and G-CSF in patients with multiple myeloma. Moreover, our cost analysis supports the use of vinorelbine as it can be administered in an outpatient setting with few days of G-CSF application and low risk of febrile neutropenia.
